Welcome to our dedicated page for Cryoport news (Ticker: CYRX), a resource for investors and traders seeking the latest updates and insights on Cryoport stock.
Cryoport, Inc. reports developments in temperature-controlled supply chain solutions for the life sciences, with recurring updates tied to regenerative medicine and cell and gene therapy support. Its platform includes the Cryoportal® Logistics Management Platform, advanced temperature-controlled packaging, informatics, specialized biologistics, biostorage, bioservices, cryopreservation services and cryogenic systems.
Company news commonly covers quarterly and annual operating results, revenue guidance, clinical-trial and commercial therapy support, Life Sciences Services and Life Sciences Products activity, MVE Biological Solutions cryogenic systems, product introductions such as Fusion freezers, and quality or regulatory certifications for therapeutic-cell transport.
Cryoport, Inc. (Nasdaq: CYRX) announced the conversion of 50,000 shares of 4.0% Series C Convertible Preferred Stock into common stock by funds affiliated with Blackstone (NYSE: BX). This conversion resulted in 1,312,860 new shares of common stock issued on February 5, 2021, part of Blackstone's original $250 million investment. Cryoport's leadership highlighted the strategic acquisitions of CRYOPDP and MVE Biological Solutions as key factors for future growth in temperature-controlled supply chain solutions, anticipating increased demand in cell and gene therapies.
Cryoport, Inc. (Nasdaq: CYRX) recently completed an underwritten public offering of 4,356,059 shares at $66.00 each, generating approximately $287.5 million in gross proceeds. This offering included an additional 568,181 shares from underwriters' full exercise of their option. The net proceeds will support general corporate purposes such as working capital, inventory development, and infrastructure expansion. The offering was executed under an effective shelf registration statement filed with the SEC.
Cryoport, Inc. (Nasdaq: CYRX) announced a public offering of 3,787,878 newly issued shares at $66.00 per share, aiming for net proceeds of approximately $234.5 million. The offering, which includes a 30-day underwriters' option for an additional 568,181 shares, is expected to close on January 25, 2021. The funds will be used for general corporate purposes, including working capital, inventory development, infrastructure expansion, and marketing. Major banks involved include Morgan Stanley and Jefferies.
Cryoport, Inc. (Nasdaq: CYRX) announced its intention to offer $200 million in common stock through an underwritten public offering, subject to market conditions. The company may grant underwriters a 30-day option for an additional 15% of shares offered. Proceeds will support general corporate purposes, including working capital and infrastructure development. The offering is supported by a previously filed automatic shelf registration with the SEC. Leading investment banks such as Morgan Stanley and Jefferies are managing the offering.
Cryoport, Inc. (CYRX) has signed a three-year agreement with the Colorado Center for Reproductive Medicine (CCRM) to enhance fertility treatments through its temperature-controlled supply chain solutions. The partnership aims to support services such as in vitro fertilization (IVF), fertility preservation, and third-party reproduction by managing cryogenic shipments of human eggs and embryos. CCRM operates 11 centers across North America, employing over 560 staff, including 40 physicians and 22 PhDs. Cryoport will also extend its logistics solutions as CCRM scales operations.
Cryoport, Inc. (NASDAQ: CYRX) reported a solid performance in Q3 2020, with revenues increasing 17% to $11.2 million. The company signed agreements for milestone acquisitions of MVE Biological Solutions and CRYOPDP, expanding global operations to 30 locations. Biopharma revenue rose 12.8% to $8.4 million, while Reproductive Medicine revenue surged 61.6% to $1.2 million. Despite a net loss of $11.4 million, cash reserves increased to $202.9 million due to successful financing activities. The company supports 517 clinical trials and anticipates strong growth entering 2021.
Cryoport, Inc. (NASDAQ: CYRX) will announce its financial results for the third quarter of 2020 on November 5, 2020, after the market closes. A comprehensive review document will also be released at 4:05 PM ET, providing details on financial and operational performance. Following the release, Cryoport will host a Q&A conference call at 5:00 PM ET, with dial-in options available. The company is focused on redefining temperature-controlled supply chain support for the life sciences industry.
Cryoport (NASDAQ: CYRX) has signed an agreement to acquire CRYOPDP, a leading provider of temperature-controlled logistics solutions, for approximately €49 million in cash. This acquisition aims to enhance Cryoport's global supply chain network, particularly in Europe, the Middle East, Africa, and Asia Pacific, regions identified as high-growth areas for biopharma and cell and gene therapies. CRYOPDP reported over €42 million in revenue in 2019 and the acquisition is expected to be immediately accretive to Cryoport's earnings. The deal is anticipated to close within 60 days, subject to standard conditions.
Cryoport (NASDAQ: CYRX) reported Q2 2020 revenues of $9.4 million, an 11% increase year-over-year, driven by its biopharma segment. The company now supports 491 clinical trials, with significant growth in biopharma despite COVID-19 disruptions. Key partnerships remain strong, including renewed agreements with Gilead and FedEx. However, Cryoport posted a net loss of $5.8 million for Q2, up from $2.5 million in 2019. The company holds $208.2 million in cash and investments, bolstered by a convertible debt offering. Future growth is supported by an expanding global supply chain network.
On August 4, 2020, Cryoport (NASDAQ: CYRX) and MEDIPAL HOLDINGS announced a multi-year strategic alliance to provide an integrated supply chain solution for regenerative medicine in Japan. This partnership aims to enhance distribution for specialty cell and gene therapies requiring strict temperature controls and tracking systems. Cryoport supports over 465 clinical trials globally, while MEDIPAL specializes in timely logistics for healthcare products across varied temperatures. The alliance seeks to improve certainty and reduce risks for clients, enabling better service for medical needs.